Acorda Therapeutics' Preclinical Pipeline Named One of the 10 Most Promising Neuroscience Projects Available for Partnering by Windhover Information Inc.

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Company’s preclinical pipeline has been selected by Windhover Information and an independent neuroscience expert as one of the top 10 most interesting neuroscience projects in development available for strategic partnering.

Back to news